Research
Hormonal
GIPR agonism mitigates the gastrointestinal adverse effects (nausea/vomiting) associated with GLP-1R agonism, thereby allowing for higher maximal tolerated doses of GLP-1-based therapies.
If you are struggling with nausea on a GLP-1 drug, switching to a combination GIP/GLP-1 drug might allow you to take a higher dose without more side effects. The GIP component helps cancel out the nausea caused by the GLP-1 component.
GoodSupportsHIGH confidence
GIPR agonism in adjunct to GLP-1R agonism mitigates the GI adverse event profile of GLP-1R pharmacology to ultimately increase both patient compliance and maximal practical dosage.
Why this rating
Supported by animal models and clinical trial discontinuation data, though exact human mechanism is noted as warranting clarification.
Source
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Aaron Novikoff et al. · Physiology · 2024
DOI 10.1152/physiol.00032.2023
narrative_reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Unimolecular GIPR:GLP-1R coagonists (e.g., tirzepatide) achieve superior body weight loss compared to GLP-1R monoagonists (e.g., semaglutide) in both diabetic and non-diabetic obese populations, with efficacy scaling with dose without compromising tolerability.Strong
- GIPR signaling in the central nervous system (specifically GABAergic neurons) is required for the body weight-lowering effects of GIP-based therapies, whereas peripheral GIPR signaling in adipose tissue has complex, context-dependent effects on lipolysis vs lipogenesis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →